← Back to feed

Arecor Therapeutics

AREC · AIM · Health Care · mcap £28m today, £28m on 30 Sep

Overhang cleared · Forming 1/2

Pattern evidence · every line sourced

Major holder places stock, 30 Sep: Close of Accelerated Bookbuild to New Orders RNS
Watch: next signal would be “Directors buy” – On-market purchase after the placing, within 120 days.

AI summary with checked claims arrives with the nightly run. These lines are the matched extracts.

All announcements

All RNS · 21 Key events · 15 Pattern signals · 1

30 Sep 26

Retail Offer to raise up to £130,000

Retail Offer to raise up to £0.13 million
RNS 9799624 ↗
30 Sep 26

Results of Placing

A separate announcement will be made shortly by the Company in relation to the Retail Offer and shall include its terms and timetable.
RNS 9799607 ↗
30 Sep 26

SIGNAL 1 Major holder places stock

Close of Accelerated Bookbuild to New Orders
Close of Accelerated Bookbuild to New Orders · RNS 9799443 ↗
30 Sep 26

Proposed Fundraising to raise up to £5.13 million

Proposed Fundraising to raise up to £5.13 million
RNS 9797856 ↗
30 Sep 26

Half-year Results

Interim results for the six months to 30 June 2026
RNS 9797694 ↗
13 Aug 26

AT278 data published in peer-reviewed journal

· Findings support AT278's potential as first ultra-rapid U500 option for insulin resistance in people with type 2 diabetes requiring high-dose therapy, regardless of BMI
RNS 9719112 ↗
18 May 26

Upcoming conference attendance

Cambridge, UK, 18 May 2026: Arecor Therapeutics plc (AIM: AREC), a clinical stage biotech company developing superior therapeutics that can reduce treatment burden and improve outcomes for people living with diabetes, obesity and other cardiometabolic...
RNS 9572067 ↗
13 Apr 26

Final Results

Cambridge, UK, 13 April 2026: Arecor Therapeutics plc (AIM: AREC), a clinical-stage biotech company developing superior therapeutics that can reduce treatment burden and improve outcomes for people living with diabetes, obesity and other cardiometabolic...
RNS 9515693 ↗
30 Mar 26

Notice of FY25 Results

Cambridge, UK, 30 March 2026: Arecor Therapeutics plc (AIM: AREC), a clinical stage biotech company developing superior therapeutics that can reduce treatment burden and improve outcomes for people living with diabetes, obesity and other cardiometabolic...
RNS 9497054 ↗
26 Mar 26

Ligand Pharmaceuticals Milestone Payment

$0.5 Million Commercial Milestone Payment From Ligand Pharmaceuticals
RNS 9492594 ↗
09 Mar 26

Arecor to present at Oppenheimer conference

Arecor to present at Oppenheimer Annual Healthcare MedTech & Services Conference
RNS 9463737 ↗
09 Feb 26

2025 Business Update

Cambridge, UK, 9 February 2026: Arecor Therapeutics plc (AIM: AREC), a biopharmaceutical company focused on drug development and enhanced delivery in diabetes and other cardiometabolic diseases, provides a business update (unaudited) for the 12 months...
RNS 9420120 ↗
06 Jan 26

Fireside Panel Discussion on Diabetes sector

Arecor and Sequel Med Tech virtual fireside panel discussion
RNS 9336757 ↗
09 Dec 25

Arecor and Sequel Med Tech to host fireside panel

Arecor and Sequel Med Tech to host virtual fireside panel discussion
RNS 9283782 ↗
04 Nov 25

Enhanced IP Coverage: AT278 & Oral Peptide Program

Arecor Enhances IP Coverage for AT278 and Oral Delivery Technology
RNS 9210216 ↗

Source: Investegate RNS archive. Quotes are short extracts. Not investment advice.